30 June 2020
Latham Advises on US$120 Million Freeline Therapeutics Series C Investment
Advising firms
Deal team
3 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Robbie McLaren Lead | Latham & Watkins LLP | Partner | corporate | London |
| Emily Cridland | Latham & Watkins LLP | Associate | Not stated | Not stated |
| Georgina Scott | Latham & Watkins LLP | Associate | Not stated | Not stated |
Stated terms
- Stated value
- USD 120m (US$120 million)
- What the figure measures
- Issue size
- Client
- Latham & WatkinsOther
- Counterparties
- Novo Holdings A/S (Investor)
Freeline Therapeutics (Other)
Eventide Asset Management (Investor)
Wellington Management Company (Investor)
Cowen Healthcare Investments (Investor)
Acorn Bioventures (Investor)
Ample Plus Fund (Investor)